Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander S Gallus

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Blood|July 16, 2008
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyHarry R Buller, Anthonie W A Lensing, Martin H Prins, et al.
Thrombosis and Haemostasis|September 2, 2016
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trialSuzanne M Bleker, Alexander T Cohen, Harry R Büller, et al.
The New England Journal of Medicine|July 2, 2013
Oral apixaban for the treatment of acute venous thromboembolismGiancarlo Agnelli, Harry R Buller, Alexander Cohen, et al.
Thrombosis and Haemostasis|May 29, 2010
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trialFrederiek F van Doormaal, Alexander T Cohen, Bruce L Davidson, et al.
BMJ (Clinical Research Ed.)|January 28, 2006
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialAlexander T Cohen, Bruce L Davidson, Alexander S Gallus, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Blood|July 16, 2008
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging StudyHarry R Buller, Anthonie W A Lensing, Martin H Prins, et al.
Thrombosis and Haemostasis|September 2, 2016
Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trialSuzanne M Bleker, Alexander T Cohen, Harry R Büller, et al.
The New England Journal of Medicine|July 2, 2013
Oral apixaban for the treatment of acute venous thromboembolismGiancarlo Agnelli, Harry R Buller, Alexander Cohen, et al.
Thrombosis and Haemostasis|May 29, 2010
Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trialFrederiek F van Doormaal, Alexander T Cohen, Bruce L Davidson, et al.
BMJ (Clinical Research Ed.)|January 28, 2006
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialAlexander T Cohen, Bruce L Davidson, Alexander S Gallus, et al.
Pageof 2